Kennedy Capital Management Inc. Sells 216,099 Shares of West Pharmaceutical Services, Inc. (WST)

Kennedy Capital Management Inc. decreased its stake in West Pharmaceutical Services, Inc. (NYSE:WST) by 72.1% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 83,766 shares of the medical instruments supplier’s stock after selling 216,099 shares during the quarter. Kennedy Capital Management Inc. owned approximately 0.11% of West Pharmaceutical Services worth $7,918,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of the company. Chatham Capital Group Inc. boosted its stake in shares of West Pharmaceutical Services by 7.8% in the second quarter. Chatham Capital Group Inc. now owns 17,300 shares of the medical instruments supplier’s stock worth $1,635,000 after buying an additional 1,245 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. purchased a new position in West Pharmaceutical Services during the second quarter worth approximately $11,461,000. Kayne Anderson Rudnick Investment Management LLC boosted its position in West Pharmaceutical Services by 11.5% during the second quarter. Kayne Anderson Rudnick Investment Management LLC now owns 34,520 shares of the medical instruments supplier’s stock worth $3,263,000 after purchasing an additional 3,560 shares in the last quarter. Bradley Foster & Sargent Inc. CT purchased a new position in West Pharmaceutical Services during the second quarter worth approximately $212,000. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its position in West Pharmaceutical Services by 0.3% during the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 10,735 shares of the medical instruments supplier’s stock worth $1,015,000 after purchasing an additional 34 shares in the last quarter. Hedge funds and other institutional investors own 91.25% of the company’s stock.

West Pharmaceutical Services, Inc. (NYSE WST) opened at 91.43 on Monday. The stock has a market cap of $6.77 billion, a P/E ratio of 39.24 and a beta of 1.13. West Pharmaceutical Services, Inc. has a 12 month low of $70.17 and a 12 month high of $99.91. The firm’s 50-day moving average price is $87.56 and its 200-day moving average price is $88.98.

West Pharmaceutical Services (NYSE:WST) last released its earnings results on Thursday, July 27th. The medical instruments supplier reported $0.66 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.01. West Pharmaceutical Services had a return on equity of 14.02% and a net margin of 11.42%. The company had revenue of $397.60 million for the quarter, compared to analysts’ expectations of $406 million. During the same quarter in the previous year, the firm posted $0.59 EPS. The firm’s quarterly revenue was up 2.5% on a year-over-year basis. On average, analysts predict that West Pharmaceutical Services, Inc. will post $2.68 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, November 1st. Shareholders of record on Wednesday, October 18th will be given a dividend of $0.14 per share. This is a boost from West Pharmaceutical Services’s previous quarterly dividend of $0.13. The ex-dividend date is Tuesday, October 17th. This represents a $0.56 annualized dividend and a yield of 0.61%. West Pharmaceutical Services’s payout ratio is presently 22.22%.

A number of equities analysts have issued reports on the company. BidaskClub downgraded West Pharmaceutical Services from a “sell” rating to a “strong sell” rating in a research report on Thursday, August 3rd. Zacks Investment Research downgraded West Pharmaceutical Services from a “hold” rating to a “sell” rating in a research report on Wednesday, July 19th. Finally, Jefferies Group LLC reiterated a “hold” rating and set a $90.00 price target on shares of West Pharmaceutical Services in a research report on Thursday, June 8th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the company. The company has an average rating of “Hold” and an average price target of $90.18.

WARNING: “Kennedy Capital Management Inc. Sells 216,099 Shares of West Pharmaceutical Services, Inc. (WST)” was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this article on another website, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this article can be viewed at https://sportsperspectives.com/2017/09/11/kennedy-capital-management-inc-sells-216099-shares-of-west-pharmaceutical-services-inc-wst.html.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply